PlaCCine ®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the ...

Prof Young says: “This is targeting the machinery of the genetic mutations that drive cancer ... For example, we measure the ...

Brisa Aschebrook-Kilfoy, Associate Professor of Family Medicine at UChicago, is an expert in conducting environmental exposure assessments. She is actively leading efforts to build resources to study ...

Keeping a record of your family's medical conditions, genetics and other key health information can help you be proactive about your health and reduce your risk of developing diseases that can run in ...

The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

A molar pregnancy, also known as a hydatidiform mole, is an abnormal human pregnancy with no embryo and an overgrowth of the ...

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, ...

Ask yourself how the genetic test results may affect your life. If the results come back positive, will you take steps to ...

Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...